After an update from management and consulting with two neurologists, Piper Jaffray analyst Danielle Brill believes the launch of GW Pharmaceuticals’ Epidiolex launch is going well. GW indicated demand is high but the majority of current prescriptions are from academic institutions, that payer coverage is expanding nicely, and that fill time is now less than two weeks, Brill tells investors in a research note titled “Expert Feedback on Epidiolex Instills Confidence in Strength of Launch.” The experts she spoke to mostly agreed. The analyst reiterates an Overweight rating on GW Pharmaceuticals with a $180 price target.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.